Esophageal Neoplasms  >>  IMF-001  >>  Phase 1
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
IMF-001 / ImmunoFrontier
NCT01003808: Safety Study of a Recombinant Protein Vaccine to Treat Esophageal Cancer

Completed
1
25
Japan
IMF-001, CHP-NY-ESO-1
ImmunoFrontier, Inc.
Esophageal Cancer
03/12
12/12
NCT01234012: Study of IMF-001 in Patients With Malignancies Expressing NY-ESO-1

Completed
1
23
US
IMF-001
ImmunoFrontier, Inc.
Solid Tumor
11/13
03/14

Download Options